Co-Diagnostics Inc Stock Price, News & Analysis

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE). This clearance follows a successful independent evaluation of the test's sensitivity and specificity. Following the CE marking, demand has surged for the ABC multiplex diagnostic, particularly as flu season approaches amidst reduced immunity predictions. The company views this approval as validation of its CoPrimer™ platform and a step toward enhancing access to affordable diagnostics.

Co-Diagnostics, Inc. (NASDAQ: CODX) will present at the Sidoti Fall Virtual Investor Conference on September 23, 2021, at 3:15 p.m. EDT. The presentation will be led by CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the event through the Co-Diagnostics website. Registration for the presentation and one-on-one meetings is available at www.sidoti.com/events.

Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's CDSCO to manufacture and sell Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics. Utilizing Co-Diagnostics' patented CoPrimer™ technology, these tests aim to accurately detect these mosquito-borne viruses, addressing a significant public health issue as the incidence of dengue has dramatically increased globally. CEO Dwight Egan emphasized the importance of accurate diagnosis for effective treatment and highlighted CoSara's prior approvals for various tests in India.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced today that CEO Dwight Egan will join a panel discussion titled "How We Can Defeat the Next Pandemic," hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. 2021 Global Investor Conference. This virtual event is scheduled for September 15, 2021, at 12:00 pm ET. Attendees can register for the conference here. Additionally, Mr. Egan and CFO Brian Brown will present a Healthcare & Biotech On-Demand session available starting September 13, 2021, at 7:00 am ET on their website.

Co-Diagnostics (Nasdaq: CODX) announced that its Logix Smart™ COVID-19 Test Kit was utilized by Italian researchers to detect SARS-CoV-2, including mutated strains, through community surveillance testing of discarded saliva samples. The peer-reviewed results were published in Science of the Total Environment. The study involved testing items like plastic cups and bottles across 20 sites in Northern Italy during the COVID-19 peak in early 2021. CEO Dwight Egan emphasized the importance of this study, highlighting the test's effectiveness in identifying viral presence in environmental samples.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will showcase its innovations at the 13th Annual Next Generation Dx Summit from August 24-26, 2021, in Washington, D.C. The summit focuses on critical issues in diagnostics, featuring streams on Point-of-Care Testing (POCT) and Liquid Biopsy. CEO Dwight Egan is scheduled to present on August 25 at 10:30 am ET, discussing a rapid PCR diagnostics platform designed for POCT applications that aim to streamline testing protocols across various environments. More information on the summit can be found at Next Generation Dx.

Co-Diagnostics, Inc. (NASDAQ: CODX) reported second-quarter financial results with revenue of $27.4 million, a 13.8% increase year-over-year, driven by the Logix Smart™ COVID-19 Test. Gross profit rose 37.6% to $24.9 million, due to improved production costs. However, operating income fell 19.8% to $11.8 million due to rising sales and marketing expenses. Net income was $9.8 million ($0.33 per share), down from $15.0 million ($0.51 per share) a year earlier. Cash reserves increased to $72.4 million. The company expects Q3 revenue between $23.0 million and $25.0 million.

Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close. The company aims to discuss these results in a conference call at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Co-Diagnostics focuses on molecular diagnostics with a patented technology for developing diagnostic tests based on nucleic acid detection. The results and call are crucial for investors seeking insights into the company's financial performance and future outlook.

Co-Diagnostics, Inc. (Nasdaq: CODX) announced the award of a new patent for its CoPrimer™ technology from South Korea's Intellectual Property Office. This adds to the company's growing portfolio of intellectual property, enhancing the protection of its molecular diagnostic tests. The CoPrimer technology underpins tests like the Logix Smart™ COVID-19 Test kit, which has sold millions globally since the pandemic's onset. Co-Diagnostics emphasizes the durability of its sales model and the significant demand from repeat customers.